Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease (NCT04639050)

🧪 Interventions in This Study

• RO7126209 (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (41 Sites)

Showing the first 25 of 41 sites.

• JEM Research LLC — Atlantis, Florida
• K2 Medical Research-Winter Garden — Clermont, Florida
• K2 Medical Research - The Villages — Lady Lake, Florida
• K2 Medical Research, LLC — Maitland, Florida
• Optimus U Corp — Miami, Florida
• Charter Research - Winter Park/Orlando — Orlando, Florida
• Advent Health Orlando — Orlando, Florida
• Alzheimer's Research and Treatment Center — Stuart, Florida
• Charter Research - Lady Lake/The Villages — The Villages, Florida
• Alzheimer?s Research and Treatment Center — Wellington, Florida
• Conquest Research, LLC — Winter Park, Florida
• Alzheimer's Research and Treatment Center - Columbus — Columbus, Georgia
• Center for Advanced Research & Education — Gainesville, Georgia
• Quest Research Institute — Farmington Hills, Michigan
• Summit Research Network Inc. — Portland, Oregon
• Abington Neurological Associates — Abington, Pennsylvania
• Kerwin Research Center, LLC — Dallas, Texas
• Heidelberg Repatriation Hospital — Heidelberg West, Victoria
• Alfred Hospital — Melbourne, Victoria
• Richmond Clinical Trials — Richmond, British Columbia
• Toronto Memory Program — Toronto, Ontario
• Centro de Investigación Clínica UC-CICUC — Santiago,
• Hospital Clinico Univ de Chile — Santiago,
• Yokohama City Minato Red Cross Hospital — Kanagawa,
• Koseikai Takeda Hospital — Kyoto,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alzheimers Disease

• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) — Birmingham, Alabama
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Birmingham, Alabama
• A Post Authorization Registry Study of Participants Treated With LEQEMBI — Vancouver, British Columbia
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Phoenix, Arizona
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Birmingham, Alabama

Explore by condition: All Alzheimers Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.